Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
Dexcom, Inc. (NASDAQ: DXCM) announces its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project to enhance health outcomes for professional truck drivers during National Diabetes Awareness Month. This initiative utilizes real-time continuous glucose monitoring via Dexcom G6 systems, integrating health data to provide personalized virtual care. The T.H.A.T. project will track health metrics of 200 truck drivers and aims to address their higher diabetes risk. This innovative model may be expanded to other high-risk workforces in Canada.
DexCom, Inc. (NASDAQ:DXCM) announced that Matt Dolan, Executive Vice President of Strategy, Corporate Development, and DexCom Labs, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:30 am (EST). The presentation will provide updates about the company and its innovative continuous glucose monitoring systems aimed at improving diabetes management.
Links to the live webcast and archived presentation will be available on the DexCom Investor Relations website.
On World Diabetes Day, Dexcom (NASDAQ: DXCM) launched a campaign to support the diabetes community through custom continuous glucose monitor (CGM) patches. Celebrities including Henry Slade, Roxy Horner, Sheku Kanneh-Mason, and Eoin Costelloe designed patches to share their personal diabetes stories. The initiative aims to promote visibility and understanding of diabetes, encouraging others to join the movement. Participants can create their designs at UK.SeeDiabetes.com, with the first 500 submissions receiving free patches. Dexcom focuses on real-time diabetes management through innovative CGM technologies.
In November, Dexcom (NASDAQ: DXCM) launches the #SeeDiabetes campaign to enhance access to diabetes care during National Diabetes Awareness Month. This initiative features celebrity advocates like Patti LaBelle and Mark Andrews, who collaborate with artists to create custom Dexcom G6 patches. The campaign aims to raise awareness of coverage challenges for diabetes technology and celebrate the resilience of those living with diabetes. The initiative aligns with World Diabetes Day, advocating for expanded access to continuous glucose monitoring technology, especially following a recent CMS proposal.
DexCom reported its Q3 2022 financial results, with revenues increasing 18% year-over-year to $769.6 million. U.S. revenue grew 17% and international revenue soared 22%. GAAP operating income reached $147.5 million (19.2% of revenue), up from $118.3 million in Q3 2021. The company updated its annual revenue guidance to $2.88 - 2.91 billion. Significant strategic moves include launching the Dexcom G7 in five countries and expanding access to CGM through NHS inclusion.
DexCom, Inc. (NASDAQ: DXCM) has launched its inaugural program, Dexcom U, aimed at supporting college athletes with diabetes. The program features 14 athletes from 11 sports, promoting representation and inspiration for aspiring athletes facing similar challenges. A survey reveals that 43% of adults with Type 1 diabetes considered quitting sports due to their condition. Dexcom U, in collaboration with ESPN's Adam Schefter, provides mentorship and a platform for these athletes. The program emphasizes the role of continuous glucose monitoring in empowering athletes to manage their diabetes effectively.
Dexcom announces the launch of its G7 Continuous Glucose Monitoring (CGM) System in the UK, Ireland, Germany, Austria, and Hong Kong, aimed at people aged two and older. The G7 features the fastest sensor warmup in the market, with no finger sticks required, and builds on the accuracy of Dexcom's previous products. A global streaming launch event showcased the device, with plans for launches in New Zealand and South Africa soon. With improved design and integration into automated insulin delivery systems, Dexcom G7 marks a significant advancement in diabetes management.
DexCom, Inc. (NASDAQ:DXCM) will release its third quarter 2022 financial results on October 27, 2022, after market close.
A conference call is scheduled for 4:30 p.m. (Eastern Time) on the same day to review performance, with a webcast available on their investor relations website.
Investors can call in at (866) 374-5140 (US/Canada) or (404) 400-0571 (International) using confirmation number 56107665#.
DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at upcoming investor conferences. The events include the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 2:35 PM (EST), and the Baird 2022 Global Healthcare Conference on September 14, 2022, at 8:30 AM (EST). Webcasts for these presentations will be available on the DexCom Investor Relations website, offering future access to the discussions.
DexCom, Inc. (NASDAQ: DXCM) has announced the promotion of Jake Leach to chief operating officer. Previously serving as chief technology officer, Leach has been instrumental in developing the company's continuous glucose monitoring (CGM) systems since 2004. The new role will see him take charge of product management and oversee operations, R&D, and quality control, reinforcing DexCom's commitment to innovation in diabetes technology. His expanded leadership aims to position DexCom for sustainable growth in providing CGM solutions to a wider audience.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
